JP2019513009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513009A5 JP2019513009A5 JP2018545230A JP2018545230A JP2019513009A5 JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5 JP 2018545230 A JP2018545230 A JP 2018545230A JP 2018545230 A JP2018545230 A JP 2018545230A JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune cell
- modified immune
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022088103A JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020057.2 | 2016-02-25 | ||
| EP16020057 | 2016-02-25 | ||
| PCT/US2017/019301 WO2017147383A1 (en) | 2016-02-25 | 2017-02-24 | Modified cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Division JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513009A JP2019513009A (ja) | 2019-05-23 |
| JP2019513009A5 true JP2019513009A5 (enExample) | 2020-04-02 |
| JP7082574B2 JP7082574B2 (ja) | 2022-06-08 |
Family
ID=55446573
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
| JP2018545230A Expired - Fee Related JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544554A Expired - Fee Related JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Ｐｄ－ｌ１に対する結合メンバー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11434294B2 (enExample) |
| EP (3) | EP4086285A1 (enExample) |
| JP (3) | JP7080819B2 (enExample) |
| KR (2) | KR20180111870A (enExample) |
| CN (3) | CN116082505A (enExample) |
| AU (2) | AU2017224843A1 (enExample) |
| BR (2) | BR112018067696A2 (enExample) |
| CA (2) | CA3014001A1 (enExample) |
| ES (1) | ES2903408T3 (enExample) |
| RU (2) | RU2018128464A (enExample) |
| SG (2) | SG11201807187XA (enExample) |
| WO (2) | WO2017147383A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| GB201617714D0 (en) | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
| RS62865B1 (sr) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Novi t-ćelijski receptori i imunoterapija u kojoj se koriste |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102523318B1 (ko) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법 |
| KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| JP2020516654A (ja) | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| CA3086187A1 (en) | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
| CA3088832A1 (en) | 2018-01-19 | 2019-07-25 | Miltenyi Biotec B.V. & Co. KG | Regulatory t cell expressing a chimeric antigen receptor |
| CN112119099A (zh) | 2018-03-02 | 2020-12-22 | Cdr-生物科技股份有限公司 | 三特异性抗原结合蛋白 |
| CN112424225B (zh) * | 2018-03-29 | 2023-08-11 | 桂林三金药业股份有限公司 | 抗pd-l1抗体及其用途 |
| JP7518771B2 (ja) * | 2018-06-04 | 2024-07-18 | ディアテーバ ソチエタ レスポンサビリタ リミタータ | 抗ｃｄ９９ダイアボディ又はｉｇｇ抗体及びそれらの使用 |
| JP2021527427A (ja) | 2018-06-21 | 2021-10-14 | ビー−モーゲン・バイオテクノロジーズ，インコーポレーテッド | 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法 |
| CN112119094B (zh) * | 2018-06-29 | 2024-11-22 | Y生物股份有限公司 | 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途 |
| AU2019301070B2 (en) | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| MX2021003744A (es) * | 2018-10-01 | 2021-06-23 | Adicet Bio Inc | Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos. |
| TW202035685A (zh) | 2018-10-17 | 2020-10-01 | 美商聖堤生物科技股份有限公司 | 組合癌症免疫療法 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US20210369776A1 (en) * | 2018-12-06 | 2021-12-02 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| WO2020135559A1 (en) * | 2018-12-26 | 2020-07-02 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| MX2021009020A (es) * | 2019-01-28 | 2021-09-28 | Xyphos Biosciences Inc | Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car. |
| TW202045544A (zh) | 2019-02-22 | 2020-12-16 | 美商戊瑞治療有限公司 | 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白 |
| CN113543792A (zh) * | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| CA3134465A1 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Of California | Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers |
| CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
| CN118344479A (zh) * | 2019-06-12 | 2024-07-16 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
| MA56467A (fr) * | 2019-07-02 | 2022-05-11 | Telix Int Pty Ltd | Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| JP2023500337A (ja) * | 2019-11-04 | 2023-01-05 | イノビオ ファーマシューティカルズ，インコーポレイティド | 脳がんを治療するための併用療法 |
| RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| AU2020396896A1 (en) * | 2019-12-02 | 2022-06-09 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-L1 and methods of use thereof |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| CA3172932A1 (en) * | 2020-03-23 | 2021-09-30 | Curigin Co.,Ltd. | Structure of oncolytic virus comprising bispecific nucleic acid molecule |
| CN115667292A (zh) * | 2020-04-06 | 2023-01-31 | 朗格生物技术公共公益股份有限公司 | 模块化合成受体和使用方法 |
| KR20230011948A (ko) * | 2020-04-17 | 2023-01-25 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 향상된 기능을 갖는 면역 세포 |
| WO2021231975A1 (en) * | 2020-05-14 | 2021-11-18 | Virtuoso Binco, Inc. | Humanized cd38 and icam1 antibodies and uses thereof |
| WO2021252654A1 (en) * | 2020-06-11 | 2021-12-16 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
| US20230227557A1 (en) * | 2020-06-25 | 2023-07-20 | Promab Biotechnologies, Inc. | Pd-l1-specific antibody and anti-pd-l1-car-t cells |
| IL299764A (en) | 2020-07-10 | 2023-03-01 | Precigen Inc | Fusion constructs and methods for using them |
| CA3197147A1 (en) * | 2020-11-04 | 2022-05-12 | Senti Biosciences, Inc. | Protein payload release |
| CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
| JP2023551482A (ja) * | 2020-11-30 | 2023-12-08 | フレッド ハッチンソン キャンサー センター | Ｐｄ－ｌ１結合ペプチド及びペプチド複合体及びそれらの使用方法 |
| EP4323389A1 (en) * | 2021-04-15 | 2024-02-21 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
| CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
| WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
| EP4376887A4 (en) * | 2021-07-30 | 2025-09-24 | Janssen Biotech Inc | MATERIALS AND METHODS FOR MAKING OR USING IL-23 R BINDING PROTEINS |
| MX2024001948A (es) | 2021-08-13 | 2024-05-17 | Inovio Pharmaceuticals Inc | Terapia combinada para tratar el cáncer cerebral. |
| CN118176017A (zh) * | 2021-10-26 | 2024-06-11 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
| EP4469069A4 (en) * | 2022-01-28 | 2026-05-06 | Univ North Carolina Chapel Hill | T LYMPHOCYTES, NATURAL KILLERS, AND THEIR METHODS OF USE |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN120518751B (zh) * | 2025-07-23 | 2025-09-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| PT2332989E (pt) | 2002-05-22 | 2015-08-05 | Esbatech Alcon Biomed Res Unit | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| DK2158315T3 (en) | 2007-06-25 | 2016-06-06 | Esbatech Alcon Biomed Res Unit | Methods of modifying antibodies and modified antibodies with improved functional properties |
| HUE038432T2 (hu) | 2008-06-25 | 2018-10-29 | Esbatech Alcon Biomed Res Unit | Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával |
| US9556265B2 (en) | 2008-06-25 | 2017-01-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| EP4209510B1 (en) * | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| EP2755487B1 (en) | 2011-09-16 | 2018-12-19 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013267161A1 (en) * | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| BR112015020516A2 (pt) * | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| CA2914829A1 (en) | 2013-06-26 | 2014-12-31 | Numab Therapeutics AG | Novel antibody frameworks |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3151854B1 (en) * | 2014-06-06 | 2020-02-26 | Memorial Sloan Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| BR112017000497B1 (pt) * | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| CA2959694C (en) | 2014-09-04 | 2023-11-21 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| EP3858991A1 (en) | 2014-09-26 | 2021-08-04 | Baylor College of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
| WO2016070119A1 (en) | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| KR102923234B1 (ko) | 2014-12-19 | 2026-02-04 | 다나-파버 캔서 인스티튜트 인크. | 키메라 항원 수용체 및 이의 사용 방법 |
| GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
-
2017
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en not_active Withdrawn
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh not_active Expired - Fee Related
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko not_active Ceased
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja not_active Expired - Fee Related
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en not_active Abandoned
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en not_active Ceased
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en not_active Abandoned
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh not_active Expired - Fee Related
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko not_active Ceased
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja not_active Expired - Fee Related
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en not_active Ceased
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525738A5 (enExample) | ||
| JP2019532017A5 (enExample) | ||
| JP2022512684A5 (enExample) | ||
| JP2019515646A5 (enExample) | ||
| JP2022111148A5 (enExample) | ||
| JP2022116230A5 (enExample) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2022504802A5 (enExample) | ||
| IL299221A (en) | Cd3 binding antibodies | |
| JP2018520657A5 (enExample) | ||
| IL263542B1 (en) | Bispecific antibodies inhibit immunological checkpoint | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2019513370A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2017522893A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| JP2020524000A5 (enExample) | ||
| JP2018528776A5 (enExample) | ||
| JP2018520993A5 (enExample) | ||
| JP2023519099A5 (enExample) | ||
| JP2019518721A5 (enExample) | ||
| IL273402B2 (en) | Antibodies against human leukocyte antigens type A2 and methods of using them | |
| JP2016531907A5 (enExample) |